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A B S T R A C T
Many epilepsies are acquired conditions following an insult to the brain such as a prolonged seizure, traumatic
brain injury or stroke. The generation of reactive oxygen species (ROS) and induction of oxidative stress are
common sequelae of such brain insults and have been shown to contribute to neuronal death and the devel-
opment of epilepsy. Here, we show that combination therapy targeting the generation of ROS through NADPH
oxidase inhibition and the endogenous antioxidant system through nuclear factor erythroid 2-related factor 2
(Nrf2) activation prevents excessive ROS accumulation, mitochondrial depolarisation and neuronal death during
in vitro seizure-like activity. Moreover, this combination therapy prevented the development of spontaneous
seizures in 40% of animals following status epilepticus (70% of animals were seizure free after 8 weeks) and
modified the severity of epilepsy when given to chronic epileptic animals.
1. Introduction
There is burgeoning evidence that oxidative stress plays a key role
in acute neurological injury such as prolonged seizures [1], stroke [2]
and traumatic brain injury [3], and in neurodegenerative disease such
as Parkinson’s [4] and Alzheimer’s disease [5,6]. Indeed, oxidative
stress during and after seizures is instrumental in immediate and
longer-term excitotoxic neuronal death [7,8]. Following prolonged
seizures, there is evidence that inhibiting oxidative stress not only
neuroprotects but also modifies the development of epilepsy [9–11].
Oxidative stress occurs following an imbalance in oxidation state
due to excessive production of free radicals or their products [e.g. re-
active oxygen species (ROS)], and decreased levels/functions of cellular
antioxidant systems [12]. Oxidative stress can therefore be reduced by
inhibiting the production of ROS, by the use of exogenous antioxidants
or by promoting endogenous antioxidant systems, in particular through
the activation of the transcription factor nuclear factor erythroid 2 -
related factor 2 (Nrf2) [13]. We have recently shown that activation of
Nrf2 through inhibition of Kelch ECH associating protein 1 (KEAP1) can
suppress the development of epilepsy in rat temporal lobe epilepsy
(TLE) models alone or in combination with an exogenous antioxidant
[9,10]. However, we hypothesise that a more effective strategy would
be both to activate endogenous antioxidant systems and also to inhibit
the production of seizure-induced ROS.
Mitochondria and ROS producing enzymes, such as NADPH oxidase
(NOX), are the main intracellular sources of ROS. Previously, mi-
tochondria were proposed to be the major generator of ROS during
epileptiform activity [14,15]. However, recent data from our group and
others have shown that NOX is the main source for ROS generation
during seizure-like activity and has a pivotal role in neurodegeneration
and in cell death seen in several animal models of epilepsy [16–20]. The
observation that persistent oxidative stress is present in acquired and
genetic epilepsies suggest that an effective antioxidant strategy could
potentially also have disease modifying effects in established epilepsy
[1].
Here we show that NOX inhibition coupled with stimulating cell
antioxidant defences through increasing Nrf2 availability is a particu-
larly potent strategy for preventing epileptogenesis and modifying
chronic epilepsy.
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2. Methods and materials
2.1. Cortical cell cultures
Mixed cortical neurons and glial cells cultures were prepared from
postnatal (P0–P1) Sprague-Dawley rat pups (UCL breeding colony)
according to a modified protocol described by Haynes [21]. Briefly, the
pups were sacrificed by cervical dislocation, and rat brains were quickly
removed; neocortical tissue was isolated and submerged in ice-cold
HBSS (Ca2+, Mg2+-free, ThermoFisher, Invitrogen, Paisley, UK). The
tissue was treated with 1% trypsin for 10min at 37 °C to dissociate cells.
The final neuronal cell suspension was plated on 25mm round cover-
slips coated with poly-L-lysine (1mg/ml, Sigma), and cultured in Neu-
robasal A medium supplemented with B-27 (ThermoFisher, Invitrogen)
and 2mM L-glutamine.
Neocortical cultures were fed once a week and maintained in a
humidified atmosphere of 5% CO2 and 95% air at 37 °C in a tissue
culture incubator.
The cultures were used for experiments at 13–17 days in vitro (DIV).
Neurons were distinguished from glia by their typical appearance using
phase-contrast imaging.
2.2. Recording solutions
All experiments were performed at room temperature, unless
otherwise mentioned, in an HEPES-buffered salt solution (aCSF), com-
position (in mM): 125 NaCl, 2.5 KCl, 2 MgCl2, 1.25 KH2PO4, 2 CaCl2, 30
glucose and 25 HEPES, pH adjusted to 7.4 with NaOH.
Experiments were carried out in the HEPES buffered salt solution
including (aCSF) or excluding MgCl2 (low-Mg2+).
2.3. Imaging of mitochondrial membrane potential (Δψm)
Rhodamine123 (Rh123) (Sigma, UK) (1 μM) was loaded into the
culture dishes for 15min before imaging. Cells were then washed 3
times prior to recordings. An increase of Rh123 signal indicates depo-
larization of mitochondria. Rh123 signals were normalized to the
baseline level (set 0) and maximum signal produced by mitochondrial
oxidative phosphorylation uncoupling with carbonylcyanide-p-tri-
fluoromethoxyphenyl hydrazone (FCCP, 1 μM; set to 100). Cells were
then washed 3 times prior to recordings. Experiments were repeated at
6 times from 3 different cultures.
2.4. Imaging of intracellular ROS generation
To evaluate rates of ROS production in the cytosol, dihydroethidium
(HEt; 5 μM) was present in all solutions throughout the experiments. No
pre-incubation was used to avoid accumulation of oxidized products.
Experiments were conducted using 3 separate cultures and repeated on
5–6 coverslips.
2.5. Neuronal death
Neurotoxicity was determined following incubation with low-Mg2+
for 2 h at 37 °C, by co-staining cells with propidium iodide (20 μM) and
Hoechst 33342 (4.5 μM) (Sigma, St. Louis, MO) in a fluorescent live/
dead assay. Experiments were conducted on 3 separate cortical cultures
and repeated on 7 coverslips for each treatment. In each treated culture
coverslip, 5 random fields were counted.
2.6. Live imaging and analysis
Fluorescence images were obtained on an epifluorescence inverted
microscope with a 20×fluorite objective. Excitation light provided by
a xenon arc lamp, the beam passing monochromator at 380,490 or
530 nm (Cairn Research, Kent, UK). Emitted fluorescence was detected
by a cooled CCD camera (Retiga; QImaging).
An increase of Rhodamine123 signal indicates depolarization of
mitochondria. Rhodamine123 signals were normalized to the baseline
level (set 0) and maximum signal produced by mitochondrial oxidative
phosphorylation uncoupling with carbonylcyanide-p-tri-
fluoromethoxyphenyl hydrazone (FCCP, 1 μM; set to 100).
Phototoxicity and photobleaching of cells was minimized by limiting
light exposure to the time of acquisition of the images. Fluorescent
images were acquired with a frame interval of 10 s. Data were analyzed
using Andor software (Belfast, UK).
HEt was excited by illumination at 530 nm. For most of the ex-
periments, we chose to perform measurements of ROS production rates
with HEt at a single wavelength, first to avoid photobleaching and
phototoxicity from excitation of cells in the range of UV light. Rates of
ROS increase were calculated at different time points (2, 10 and 15min)
after exposure to low-Mg2+ and were compared with rates recorded
during a 1–3min aCSF exposure period referred to as baseline.
2.7. Animals and surgery
Animal experiments were conducted in accordance with the
Animals (Scientific Procedures) Act 1986, and approved by the local
ethics committee. Male Sprague-Dawley rats (220–310 g) were in-
dividually housed with free access to food and water in 12 h light/dark
cycles throughout the study. Animals were acclimatised to the animal
house for at least 7 days before experimental use.
Male Sprague–Dawley rats were anaesthetized using isoflurane and
placed in a sterotaxic frame (Kopf, CA, USA). At the start of surgery,
Buprenorphine (0.2mg/kg; SC) and Metacam (1mg/kg; SC) were ad-
ministered for pain relief. An electrocorticography (ECoG) transmitter
(A3028, Open Source Instruments) [30] was implanted subcutaneously.
A subdural intracranial recording electrode was positioned above the
right hippocampus [2.5mm lateral and 4mm posterior of bregma
[22]], and a reference electrode was implanted in the contralateral
hemisphere (2.5 mm lateral and 6mm posterior of bregma). The elec-
trodes were fixed to the skull with three skull screws and tissue glue,
followed by dental cement. Immediately after surgery, 3–5ml of
warmed Ringer’s solution and Amoxicillin (Betamox LA, 100mg/kg)
was administered subcutaneously. Rats recovered for 7–10 days before
initiation of the experiment. Rats were housed separately in Faraday
cages and ECoG was recorded continuously for up to 18 weeks post-
surgery.
Abbreviations
aCSF Artificial cerebrospinal fluid
AEBSF 4-(2-aminoethyl)-benzenesulfonyl fluoride
ECoG Electrocorticography
HEt Dihydroethidium
KA Kainic acid
KEAP1 Kelch ECH associating protein 1
FCCP Carbonylcyanide-p-trifluoromethoxyphenyl hydrazine;
NOX NADPH oxidase
NOX2 NADPH oxidase 2
Nrf2 Nuclear factor erythroid 2-related factor 2
Rh123 Rhodamine123
ROS Reactive oxygen species
SE Status epilepticus
TAC Total antioxidant capacity
TLE Temporal lobe epilepsy
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2.8. Kainic acid-induced status epilepticus
Status epilepticus (SE) was induced using kainic acid (KA) according
to a previously described protocol [23]. Briefly, rats were hourly in-
jected intraperitoneally with KA (Tocris Bioscience, Bristol, UK) dis-
solved in sterile 0.9% saline (10mg/ml) at a dose of 5mg/kg until class
III, IV, or V seizures were evoked (scored according to a modified Ra-
cine’s scale [24,25]. Once an animal began showing excessive inactivity
or excessive activity (i.e. exaggerated running or jumping), or had more
than 10 class IV/V seizures/h, subsequent injections were delayed or
reduced to 2.5 mg/kg to avoid excessive toxicity and mortality. The
endpoint for KA treatment was considered either when animals have
reached class V seizure (i.e. excessive rearing with concomitant fore-
limb clonus and fall over) or when the total dose of KA reached 45mg/
kg.
Animals were included in the study if there was continuous epi-
leptiform activity for 2 h, during which spike frequencies were more
than 2 Hz, and spike amplitude was at least 3 times background. For
rats that were not ECoG monitored, duration of SE was measured based
on behavioural manifestation. Start of the status was considered when
the rat experienced full motor seizure with loss of postural control and
falling.
2.9. Drugs administration
Following 2 h of status epilepticus, rats were randomised to treat-
ment with either vehicle (10% DMSO/sterile saline), AEBSF (Sigma,
50mg/kg), RTA 408 (25mg/kg) or a combination of both drugs. RTA
408 was synthesized by Reata Pharmaceuticals, Inc. In the multiple
dose experiment, control animals were treated with equivalent number
and volume of injections of vehicle.
2.10. Electrocorticography analysis
The electrocorticography (ECoG) was acquired from a subdural
electrode continuously for 24 h, 7 days per week, using hardware and
software from Open Source Instruments (for details of electrode pla-
cement please refer to section Surgery). The seizure detection analysis
was performed as previously described [10]. Briefly, ECoG was seg-
mented into 4 s epochs and six different metrics calculated (power,
intermittency, coastline, coherence, asymmetry, and power between 12
and 30 Hz). Each metric was mapped onto an interval of 0–1, and
subsequently compared to a user-generated seizure library, consisting
of seizures of at least 3 different animals. Animal specific libraries were
generated as soon as at least 3 seizures per animal were detected.
Epochs were mapped as seizure-like events, if the Euclidean distance
was less than 0.2 of a validated seizure epoch. If a seizure was detected
by fewer than three 4 s epochs, the seizure was added to the library. All
seizures were validated by a researcher blinded to treatment. Seizures
were characterized by the appearance of high frequency (> 2Hz)
spikes with progression of the spike frequency, rhythmic spike wave
discharges with amplitudes at least three times that of baseline ECoG
that lasted for a minimum of 10 s. All electrographic seizures were
confirmed by visual inspection. A selection of> 60% of seizures were
also characterised by video monitoring in order to determine the be-
havioural correlate of the ECoG changes, using a time-locked CCTV
camera system, by a researcher blinded to treatment.
Fig. 1. Combination of antioxidant therapies is neu-
roprotective in vitro.
(A) Representative image of synchronous oscillatory
Ca2+ signal in neurons indicating seizure like ac-
tivity induced by replacement of artificial CSF (aCSF)
with low Mg2+ aCSF. (B) Normalised Rhodamine123
fluorescence of neurons 10, 20 and 30min treated
with aCSF (n=6 experiments (exp.)], low Mg2+
(n=6 exp.), and treated acutely with AEBSF either
alone (50 μM; n= 6 exp.) or with RTA (RTA 408,
200 nM, preincubation for 24 h; n=6 exp., F
(3,20)= 30.201, P < 0.001). (C) Normalized rates
of ROS generation at different time points in neurons
exposed to aCSF (n=5 exp.), low Mg2+ (n=5 exp.)
or neurons treated acutely with AEBSF either alone
(50 μM; n= 6 exp.) or with RTA 408 (200 nM, pre-
incubation for 24 h; n=6 exp., F(3,18)= 61.299,
P < 0.001). Note that the combination therapy has
a greater effect at later time point (15min) than
AEBSF only (P=0.015). (D) The percentage of
neuronal death in cultures following 2 h exposure to
aCSF (n= 7), low Mg2+ (n= 7), and treatment with
AEBSF either alone (50 μM; n= 7 exp.) or with RTA
408 (200 nM, preincubation for 24 h; n= 7 exp., F
(3,24)= 19.699, P < 0.001]. Combination of both
treatments has a greater effect versus single treat-
ment (P=0.029). Data (mean ± s.e.m.) were ana-
lysed by either repeated measures one-way ANOVA
(B and C) or one-way ANOVA (D) followed by
Tukey's post hoc test. *P < 0.05, **P < 0.01 and
***P < 0.001 versus low Mg2+ condition.
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2.11. Total antioxidant capacity
Total antioxidant capacity (TAC) was determined using a commer-
cially available assay kit (Abcam ab65329) which utilizes the conver-
sion of Cu2+ ions to Cu+ through endogenous protein and small mo-
lecule antioxidants, standardized to Trolox equivalents. Brain tissue
(100mg of cortex; 50mg of hippocampus) was homogenized in cold
PBS, centrifuged at 4 °C for 10min at 10,000×g and supernatant was
used for analysis of TAC. Plasma was directly used for the assay.
Samples were diluted (1:20) in sterile deionized water, and 10 μL of
samples and 100 μL of Trolox standard were added to each well of a 96-
well plate. The reaction was initiated by adding 100 μL of Cu2+
working solution to each well, and mixing the plate on an orbital shaker
for 90min at room temperature shielded from light. Colorimetric ac-
tivity was measured by optimal density at 570 nm and antioxidant ca-
pacity was calculated against the linear Trolox standard calibration
curve (1–20 μM Trolox).
2.12. Statistical analysis
All statistical analysis was performed with IBM SPSS 25 or Graph
Pad Prism 6.01. All data are expressed as the mean ± s.e.m. Data were
analyzed using unpaired Student’s t-test, Mann-Whitney U test, re-
peated-measures ANOVA, or generalized log-linear mixed model with
random effect of animal (autoregressive covariance) and fixed effects of
treatment group, week, and the interaction between treatment group
and week. The choice of parametric or nonparametric test followed a
Kolmogorov–Smirnov test. Sample sizes were chosen based on our
previous experiences in the calculation of experimental variability. The
numbers of animals used are described in the corresponding figure le-
gends. The significance level was set to an α-error of P < 0.05.
3. Results and discussion
3.1. Neuroprotective effects of combination antioxidant therapies in vitro
To investigate the neuroprotective effect of antioxidant therapies in
vitro, epileptiform activity was induced by omission of magnesium
(Mg2+) from culture media of mixed cortical neurons and glial cultures.
Epileptiform activity increases mitochondrial depolarization and rate of
ROS generation (Fig.1A-C, B: F(3,20)= 30.201, P < 0.001; C: F
(3,18)= 61.299, P < 0.001, repeated measures one-way ANOVA). We
previously reported that Nrf2 activation using a novel cyanoenone
triterpenoid, RTA 408, prevented mitochondrial depolarization and
reduced the rate of ROS generation in neurons during epileptiform
activity [10]. Here, we asked whether NOX inhibition with 4-(2-ami-
noethyl)-benzenesulfonyl fluoride (AEBSF) can also reduce mitochon-
drial depolarization, rate of ROS generation and neuronal death, and
whether its effect is enhanced by RTA 408.
Under basal conditions, Nrf2 is negatively regulated by Keap1
which forms the Keap1-Nrf2 complex, and promotes the proteasomal
degradation of Nrf2. Upon treatment with RTA 408 (or other electro-
philes), oxidation of cysteine sensors of Keap1 cause conformational
changes to the Keap1-Nrf2 complex and drive the dissociation of Nrf2
from Keap1. Nrf2 then translocates into the nucleus, where it binds to
the antioxidant response element of target genes, which leads to en-
hanced expression of downstream antioxidant enzymes, and is a rela-
tively slow process. In contrast, AEBSF is an NADPH oxidase inhibitor.
We have previously shown that seizure like activity leads to NADPH
oxidase 2 (NOX2) activation [17]. AEBSF inhibition of NOX2 is medi-
ated via inhibition of its assembly [26], which is a rapid process ne-
cessary for ROS production [27]. AEBSF was therefore used as an acute
treatment, whilst RTA 408 was used chronically.
Neuronal cultures were treated with AEBSF (50 μM, acutely) with or
without RTA 408 (200 nM, pre-incubated for 24 h) following exposure
to low Mg2+ medium. AEBSF almost completely prevented the seizure-
like activity induced mitochondrial membrane potential (ΔΨm) depo-
larization, either alone, or when co-administered with RTA 408
(Fig. 1B). We then showed that, in keeping with a previous report [17],
inhibition of NOX activation by AEBSF significantly decreased the rate
of ROS generation 2, 10, and 15min after exposure to low Mg2+
(Fig. 1C).
Interestingly, the combination of both drugs had a greater effect
(versus AEBSF alone) on reducing ROS generation at a later time point
(15min, P=0.015, repeated measures one-way ANOVA, Tukey’s post
hoc). We then asked whether inhibition of NOX is neuroprotective.
Neuronal cultures exposed to low Mg2+ media for 2 h showed a sig-
nificantly higher extent of neuronal loss when compared to cultures
exposed to artificial CSF (aCSF, Fig. 1D). Inhibition of NOX with AEBSF
(50 μM) significantly reduced low Mg2+ induced cell death (Fig. 1D,
P=0.023, one-way ANOVA with Tukey’s post-hoc), as was the com-
bination of both drugs (Fig. 1D, P < 0.001, one-way ANOVA with
Tukey’s post-hoc). Furthermore, co-treatment with RTA 408 (200 nM,
24 h preincubation) and AEBSF (50 μM) showed a greater neuropro-
tective effect compared to AEBSF alone (18.3% ± 1.4 vs.
26.5% ± 1.4, respectively, P=0.029, one-way ANOVA with Tukey’s
Fig. 2. Combination antioxidant therapy increases total antioxidant capacity following status epilepticus.
Total antioxidant capacity normalized to Trolox standard in plasma (A), cortex (B) and hippocampus (C) of rats 24 h following KA induced SE (2 h). A-C: n= 6, data
are expressed as mean ± s.e.m, (A: F(4,25)= 16.625, P < 0.001; B: F(4,25)= 2.389, P=0.078; C: F(4,25)= 22.594, P < 0.001), one way-ANOVA followed by
Tukey’s post hoc. *P < 0.05, **P < 0.01, ***P < 0.001 vs. KA + Vehicle group. n.s. P > 0.05.
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post-hoc).
3.2. Effects of antioxidant therapies on total antioxidant capacity in vivo
Thus, the combination of NOX inhibition and Nrf2 activation could
completely prevent the metabolic and excitotoxic consequences of sei-
zure-like activity in vitro. We next determined the effect of this com-
bination antioxidant therapy on total antioxidant capacity following in
vivo status epilepticus (SE). Combined non-enzymatic (small molecules
and proteins) antioxidant capacity, termed Total Antioxidant Capacity
(TAC), can be considered as a cumulative index of antioxidant status
[28]. Following 2 h of kainic acid (KA) induced SE, rats were rando-
mised to a single administration of either vehicle, AEBSF 50mg/kg,
RTA 408 25mg/kg, or a co-treatment of both drugs. TAC was measured
in plasma, cortex and hippocampus of sham operated animals as well as
treated animals 24 h post SE. Following SE, TAC was significantly re-
duced in plasma and the hippocampus of vehicle treated animals
(60% ± 7 (P=0.033, one-way ANOVA followed by Tukey’s post hoc)
and 56% ± 5 (P=0.021, one-way ANOVA followed by Tukey’s post
hoc), respectively) in comparison to sham operated animals (no SE).
Inhibition of NOX by AEBSF had no significant impact on TAC in
plasma, cortex or hippocampus (Fig. 2A–C, KA + Vehicle vs.
KA + AEBSF A: P=0.593, B: P=0.925, C: P=0.706, one way-
ANOVA followed by Tukey’s post hoc). RTA 408 completely restored
TAC in both plasma and hippocampus (Fig. 2A, C; A: P=0.012, C:
P=0.002, one way-ANOVA followed by Tukey’s post hoc). Moreover,
in rats treated with the combination of RTA 408 and AEBSF, TAC was
increased to supranormal levels, and was 2–3 times higher in plasma
and hippocampus compared to vehicle group (Fig. 2A, C; A:
157% ± 15 vs. 60% ± 7, P < 0.001, one-way ANOVA with Tukey’s
post hoc; C: 172% ± 17 vs. 56% ± 5 , P < 0.001, one-way ANOVA
with Tukey’s post hoc). Interestingly, despite TAC levels in vehicle
treated animals was not significantly reduced in the cortex (compared
to sham group), the combination of RTA 408 and AEBSF significantly
increased the TAC in the treated animals (Fig. 2B; P = 0.047,
KA + Vehicle vs. KA + RTA + AEBSF vs., one way-ANOVA followed
Fig. 3. Combination of NOX inhibition and
Nrf2 activation suppresses the development
of epilepsy following status epilepticus in
rats.
(A) Bar charts of seizure frequency (seizures
\week; mean ± s.e.m) of animals following
KA induced status epilepticus (2 h), treated
immediately after termination of SE
(Diazepam 5mg/kg) with single adminis-
tration of either vehicle (10% DMSO/saline;
n= 10), RTA 408 25mg/kg (n=7), AEBSF
50mg/kg (n= 7) or RTA 408 25mg/kg and
AEBAF 50mg/kg (n= 10). F
(3,300)= 8.005, P < 0.001 by generalized
log-linear mixed model followed by se-
quential Bonferroni post hoc test.
*P < 0.05, vs. Vehicle; #P < 0.05, RTA
408 + AEBSF vs. RTA 408; ^P < 0.05, RTA
408 + AEBSF vs. AEBSF. (B) Cumulative
number of seizures of animals in A. Data are
plotted on a logarithmic scale after in-
crementing each total seizure count by 1 to
avoid zero values. *P < 0.05, **P < 0.01,
***P < 0.001, Student’s t-test (C)
Combination therapy increases the latent
period, F(3,24)= 11.197, P < 0.001, by
one-way ANOVA followed by Tukey’s post
hoc, ***P < 0.001 vs. KA + Vehicle
group. (D) The pie charts illustrate percen-
tage of animals seizure free for the whole
study and for the last 5 weeks following KA
induced status epilepticus treated with ei-
ther vehicle (left) or with combination of
RTA 408 (25mg/kg) and AEBSF (50mg/kg)
(right). (E) Normalized seizure frequency
(seizures\week; mean± s.e.m) of animals
following KA induced SE (2 h) treated with
either vehicle (n=6; red) or with combi-
nation of RTA 408 (25mg/kg) and AEBSF
(50mg/kg) (n= 6; blue) for 3 days, 12
weeks after SE. F(1,100)= 6.737,
P=0.011 by generalized log-linear mixed
model on weeks 1–10, followed by sequen-
tial Bonferroni post hoc test). *P < 0.05,
**P < 0.01 (F) Cumulative number of post-
treatment seizures (mean ± s.e.m) for the
two groups in E. P=0.022 Student’s t-test.
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by Tukey’s post hoc).
Using a dose of AEBSF that had a non-significant effect on TAC in
hippocampus, the effect of RTA 408 on TAC was increased by ap-
proximately 50%, suggesting a synergistic effect of the combination
therapy.
3.3. Effect of combination antioxidant therapy on epileptogenesis
We next asked if NOX inhibition in combination with Nrf2 activa-
tion can suppresses the development of epilepsy following SE in rats
and is superior to either intervention alone in a randomised, control
trial. We induced SE in rats using repeated low doses of KA, according
to a previously reported protocol [23]. Following 2 h of SE, rats were
randomly assigned to treatment with single dose of either vehicle, RTA
408 (25mg/kg), AEBSF (50mg/kg) or co-treatment with both drugs.
The electrocorticogram (ECoG) was recorded from all animals for up to
12 weeks following the first spontaneous seizure. Vehicle treated ani-
mals developed a progressive increase in seizure frequency over time.
Rats treated with single administration of either AEBSF (50mg/kg) or
RTA 408 (25mg/kg) had a decrease in seizure frequency (Fig. 3A),
however, this effect was significant only at later time points (6–12 and
10–12 weeks after the first spontaneous seizure, respectively). Im-
portantly, seizure frequency in rats treated with both drugs was dra-
matically decreased from 2 to 12 weeks after the first seizure (Fig. 3A).
The cumulative number of seizures was significantly decreased in all
treatment groups (Fig. 3B, KA + Vehicle vs. KA + RTA P = 0.0249,
KA + Vehicle vs. KA + AEBSF P = 0.008, KA + Vehicle vs.
KA + RTA + AEBSF P < 0.001, Student’s t-test). As predicted, the
combination therapy was significantly more effective than either in-
tervention alone.
Moreover, rats treated with vehicle, RTA 408 or AEBSF alone had no
difference in the latency period (time from the day of KA treatment to
the first electrographically recorded seizure), whilst rats co-treated with
RTA 408 and AEBSF had an increased latency period by 265% (from
10 ± 2 days to 27 ± 4 days; Fig. 3C, P < 0.001, Student’s t-test).
Four of 10 rats co-treated with both drugs had no seizures for the
whole 12 week study period compared to only 1 of 10 treated with
vehicle. Since RTA 408 has a delayed effect and to avoid the confounder
of acute drug effects, we determined the seizure frequency 2 months
after drug administration. From weeks 8–12, 7 of 10 animals treated
with combination therapy were seizure free, compared to only 1 of 10
animals treated with vehicle (Fig. 3D). For the combination therapy,
odds ratio for being seizure free (weeks 8–12) compared to vehicle
treatment was 21 (95% CI=1.8–248).
In those rats, in whom we examined neuronal damage in the hip-
pocampus, the combination therapy resulted in marked neuroprotec-
tion (Suppl Fig.1) similar to that observed by us for each therapy in-
dividually [10,29].
3.4. Effect of combination antioxidant therapy on chronic epilepsy
To test the therapeutic efficacy of the antioxidant therapy on
chronic epilepsy, we performed a randomized, blinded trial in a model
of TLE induced by systemic KA injection. Rats were implanted with
wireless electrocorticography (ECoG) transmitters 10–12 weeks after
the induction of SE by intraperitoneal KA. After recording baseline
seizure activity for 3 weeks, 12 epileptic animals were randomized to
treatment with either vehicle, or a combination of RTA 408 (25 mg/kg)
and AEBSF (50 mg/kg), as a single daily dose over 3 days. ECoG re-
cordings were continued for a further 11 weeks. During the baseline
period, there was no significant difference in seizure frequency between
the two groups (vehicle median = 5.9 (IQR 5.7–6), RTA + AEBSF
median = 5.8 (IQR 5.5–6.3); Mann Whitney U test, P=0.125).
The combination antioxidant therapy significantly decreased the
normalized (to baseline) seizure frequency compared to vehicle treated
animals following treatment (generalized log-linear mixed model on
weeks 1–10, treatment group*week interaction effect: F
(1,100)= 6.737, P=0.011; Fig. 3E). In addition, the cumulative
number of seizures experienced per animal post treatment was sig-
nificantly decreased (Fig. 3F, P=0.022 Student’s t-test).
Epileptogenesis is associated with well recognised structural
changes which will have occurred by the time we are treating the es-
tablished epilepsy. These (such as cell loss) will not be reversed by our
treatment, possibly explaining the lesser effect of late treatment com-
pared to early treatment.
4. Conclusion
Combination therapy inhibiting ROS generation via NOX and in-
creasing antioxidant defences via Nrf2 activation prevents seizure in-
duced mitochondrial depolarization, ROS generation and neuronal cell
death in vitro and was more effective than either intervention alone.
Further, we showed that a combination of both NOX inhibition and
Nrf2 activation is the most effective mean of increasing antioxidant
capacity following KA-induced SE in vivo, and prevents the develop-
ment of epilepsy and also modifies chronic epilepsy.
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